← Human Trials & Peer-Reviewed Studies
Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.
Plain-language guide to PMID 17727392 (2007): double-blind randomized controlled trial of Glucagon in 32 volunteers.
Key Facts
- PMID
- 17727392
- Journal
- Neurogastroenterology and motility
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Andrews CN et al. (9 authors)
- DOI
- 10.1111/j.1365-2982.2007.00923.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Glucagon.
Because GLP-1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, the researchers assessed the effects of a GLP-1 agonist and yohimbine, an alpha(2)-adrenergic antagonist, on gastric volumes in humans.
Who Took Part
According to the abstract, 32 volunteers were involved.
PubMed indexes the participants as adults, both men and women.
In this double-blind study, 32 healthy volunteers were randomized to placebo, a GLP-1 agonist, yohimbine or GLP-1 and yohimbine.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.
Blinding on both sides kept the volunteers and researchers unaware of who received Glucagon.
Some volunteers received a placebo instead of Glucagon, giving a reference point.
Gastric volumes (fasting predrug and postdrug, and postprandial postdrug) were measured by (99m)Tc single photon emission computed tomography imaging.
Plasma catecholamines and haemodynamic parameters were assessed.
What Was Measured
Because GLP-1 inhibits intestinal motility by stimulating the sympathetic nervous system in rats, the researchers assessed the effects of a GLP-1 agonist and yohimbine, an alpha(2)-adrenergic antagonist, on gastric volumes in humans.
PubMed files the paper under topics including Adrenergic alpha-Antagonists, Catecholamines, Glucagon-Like Peptide 1, Postprandial Period, Stomach, Sympathetic Nervous System and Tomography, Emission-Computed, Single-Photon.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 32 volunteers.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2007 (Neurogastroenterology and motility), a journal based in England.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.